Vance Thompson Vision Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04281862
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Brandon Baartman | Mitchel Ibach | Vance Thompson Vision | Vance Thompson Vision - MT | Vance Thompson Vision ND | Vance Thompson Vision NE